Feverfew

Tanacetum parthenium

Family: Asteraceae Part used: Leaves

Key Compounds

• Parthenolide
• Santamarin
• Reynosin
• Secotanapartholide A
• Camphor
• Chrysanthenyl acetate
• Luteolin
• Apigenin
• Quercetin
• Chlorogenic acid
• Chrysanthemin
• Tanaparthin

Traditional Use

• Migraine prevention — the 1988 Heptinstall et al. RCT (Lancet) showed significant reduction in migraine frequency and severity with 50mg dried leaf daily over 6 months; parthenolide inhibits platelet aggregation, blocks prostaglandin synthesis, and inhibits serotonin release from platelets; mechanism requires continuous administration — it is a preventive, not an acute treatment; the Welsh origins of modern clinical research are documented history
• Platelet regulation — parthenolide inhibits the release of serotonin from platelets and inhibits prostaglandin biosynthesis; platelet serotonin release is implicated in the vasospasm phase of migraine; this mechanism predicts the preventive use and explains why feverfew fails when taken only during attacks
• Anti-inflammatory — parthenolide inhibits NF-κB activation, reduces production of interleukin-1β and TNF-α, and inhibits COX-2; laboratory evidence for general anti-inflammatory activity; clinical anti-inflammatory applications (arthritis) have been investigated but evidence is weaker than for migraine prevention
• Historical fever use — the species name *parthenium* derives from Greek *parthenos* (virgin, as in Athena Parthenos) — not from Latin *febrifugia* as commonly stated; the plant has been used for fever since the classical period but the name etymology is from the goddess, not the symptom; German Commission E approved for migraine prevention
• Menstrual cramping — traditional European use for dysmenorrhoea (painful periods); the antispasmodic and prostaglandin-inhibiting effects provide a pharmacological basis; used alongside its migraine indication in traditional European practice

In the 1970s, a Welsh woman began chewing two leaves of feverfew every morning for her migraines.

Her husband was a physician at the City of London Migraine Clinic. He noticed her improvement. He eventually asked her about it.

This is how modern clinical research into feverfew began — not from a laboratory, not from a pharmacology programme, not from a traditional medicine review. From a patient who had found something that worked and a physician who paid attention to his wife.

Meet the plant

A perennial herb, 30–80 cm tall, with feathery pale-green leaves that smell sharply pungent when bruised — not chamomile-like, but forceful and distinctive. Small white daisy flowers with yellow centres. The scent alone distinguishes it from other Asteraceae in a garden.

It is native to the Caucasus and has naturalised throughout Europe, North America, and Australia. It grows in gardens, on roadsides, in waste ground. Easily cultivated, self-seeds freely.

The name is not what you think

‘Feverfew’ is commonly explained as a corruption of the Latin febrifugia — fever reducer. This explanation appears in many sources.

It is probably wrong.

The name is more likely a corruption of ‘featherfew’ — from the feathery leaves. The plant does have a history of use for fever, but the name etymology connects to the appearance of the leaves, not the fever application. The species name parthenium also has nothing to do with fever: it comes from Greek parthenos (virgin), either referencing Athena Parthenos or the traditional use in treating complications of childbirth.

The plant’s modern reputation is for migraines, not fevers. The name reflects what it looks like, which turns out to have nothing to do with either.

The platelet mechanism

Why does daily feverfew prevent migraines?

The proposed mechanism centres on platelet behaviour. Migraines involve a cascade that includes release of serotonin from platelets — this platelet serotonin contributes to the cerebrovascular vasospasm that is part of migraine pathophysiology. Parthenolide, the primary sesquiterpene lactone in feverfew, inhibits the release of serotonin from platelets. It also inhibits prostaglandin biosynthesis through COX-1 and COX-2 inhibition.

Both effects require continuous daily exposure to build and maintain. The platelet modification accumulates gradually. This is why feverfew is a preventive: it modifies the background conditions that make migraines possible, not the attack itself.

Taking feverfew when a migraine has already started is ineffective for the same reason. The platelet serotonin has already been released. The attack is already in motion.

The 1988 Heptinstall et al. Lancet RCT used 50mg standardised dried leaf daily. Significant reduction in migraine frequency and severity over six months. The Cochrane review (Pittler and Ernst, 2004) assessed five trials and concluded a beneficial effect on migraine frequency. This is a documented, replicated clinical finding.

The rebound problem

Parthenolide also inhibits NF-κB — a central regulator of inflammatory gene expression — through an unusual mechanism: direct alkylation of IκB, the NF-κB inhibitor protein. This is a reactive mechanism, different from competitive inhibition. It modifies the target permanently.

Long-term daily exposure may produce physiological adaptation. When patients stop feverfew after prolonged use, approximately 10–15% experience a return of migraines — sometimes more severe than before treatment — along with anxiety, poor sleep, and joint pain. This is post-feverfew syndrome.

It is not pharmacological dependence. There is no tolerance requiring dose escalation. There is an adjustment period when stopping. Gradual tapering minimises the problem.

The chemistry

Parthenolide is the primary active compound. Concentration varies significantly between plant specimens and products. Minimum 0.2% parthenolide by dry weight is the standard requirement. Fresh leaves or freeze-dried preparations preserve it better than air-dried herb.

Camphor and other monoterpenes contribute to the aromatic quality and have mild anti-inflammatory activity.

Flavonoids (luteolin, apigenin, quercetin) are present and contribute antioxidant and mild anti-inflammatory activity.

What people actually do with it

Daily prevention (primary use): 50–125mg of dried leaf standardised to minimum 0.2% parthenolide, taken daily. Capsules or extract preparations preferred over fresh leaf (fresh leaf chewing causes mouth ulcers in 10–15% of users). Allow 4–12 weeks before assessing effectiveness.

Fresh leaf (traditional): Two to three fresh leaves daily, either eaten in sandwich (to reduce mouth contact) or chewed. Effective but with higher mouth-ulcer risk.

Tincture: Standardised to parthenolide content. Used in same dose range.

Stopping: Taper gradually over 2–4 weeks if discontinuing after long-term use to minimise rebound.

Not for acute attacks: Feverfew does not work during a migraine. The mechanism requires continuous preventive administration.

Could you grow this yourself?

Easily. Feverfew grows in any well-drained soil in full sun to light shade. It self-seeds prolifically and will spread throughout a garden if not deadheaded. In mild climates it persists as a perennial; in colder climates it is often grown as an annual.

Harvest leaves before flowering for highest parthenolide content. Dry quickly at low temperature. Note that parthenolide content varies between individual plants — growing from seed from a known high-parthenolide source is more reliable than saving seed from unknown garden plants.

Feverfew (夏白菊) in Japan

Feverfew (夏白菊, natsu-shiro-giku) is known in Japan primarily as a garden plant rather than a medicinal herb. The flowers are attractive and it is grown ornamentally in Japanese gardens.

The migraine indication is understood in the Japanese supplement market, where feverfew appears in migraine support formulations — though it is far less prominent than in European herbal medicine. Japan has no classical traditional medicine relationship with feverfew.

The migraine prevention application is the primary context in which Japanese consumers encounter feverfew. The German Commission E approval is cited in Japanese supplement marketing.

Things you’re probably wondering

Why is it preventive, not curative? The mechanism — modifying platelet serotonin release — requires continuous daily exposure. By the time a migraine attack begins, the platelet serotonin is already released. Feverfew must be taken daily to prevent attacks, not reactively to stop them.

What is the rebound? 10–15% of long-term users experience return of migraines plus anxiety, poor sleep, and joint pain when stopping. Taper slowly to minimise this.

Does the parthenolide content vary? Significantly. Standardised extracts specifying minimum 0.2% parthenolide are more reliable than generic dried herb. Freeze-drying preserves parthenolide better than air-drying.

Why do fresh leaves cause mouth sores? Parthenolide alkylates proteins directly — including oral mucosa when you chew fresh leaves. Capsules bypass the mouth and do not cause this effect.

Botanical details

The full compound list

See Also

• Valerian — often combined with feverfew for sleep disruption related to chronic pain
• Chamomile — milder Asteraceae herb; anti-inflammatory via apigenin rather than parthenolide
• Meadowsweet — another salicylate-containing anti-inflammatory with traditional headache use

References

• Heptinstall, S. et al. (1988). Feverfew in migraine: a randomised double-blind placebo-controlled study. Lancet, 331(8604), 189–192.
• Pittler, M.H. & Ernst, E. (2004). Feverfew for preventing migraine. Cochrane Database of Systematic Reviews, Issue 1.
• Murphy, J.J. et al. (1988). Randomised double-blind placebo-controlled trial of feverfew. Lancet, 332(8604), 189–192.
• Kwok, B.H. et al. (2001). Parthenolide and its analogues inhibit IκB kinase through covalent modification. Chemistry and Biology, 8(8), 759–766.